CD73 Promotes Chronic Lymphocytic Leukemia
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Animal Experimentation
2.2. Reagents and Cell Culture
2.3. Genomic and Transcriptomic Analyses
2.4. Flow Cytometry
2.5. Statistical Analysis
3. Results
3.1. CD73 and CD39 Are Upregulated on Non-Leukemic Lymphocytes upon CLL Progression
3.2. CD73 Deficiency Prolongs Survival of Eµ-TCL1 Male Mice in an IFN-γ-Dependent Manner
3.3. A2a Adenosine Receptor Signaling Drives PD-L1 Expression on CLL Cells
3.4. Adenosine Signaling Is Associated with Increased PD-L1 Expression
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Dong, Y.; Shi, O.; Zeng, Q.; Lu, X.; Wang, W.; Li, Y.; Wang, Q. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp. Hematol. Oncol. 2020, 9, 14. [Google Scholar] [CrossRef] [PubMed]
- Catovsky, D.; Wade, R.; Else, M. The clinical significance of patients’ sex in chronic lymphocytic leukemia. Haematologica 2014, 99, 1088–1094. [Google Scholar] [CrossRef] [PubMed]
- Ramsay, A.G.; Clear, A.J.; Fatah, R.; Gribben, J.G. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: Establishing a reversible immune evasion mechanism in human cancer. Blood 2012, 120, 1412–1421. [Google Scholar] [CrossRef]
- Riches, J.C.; Davies, J.K.; McClanahan, F.; Fatah, R.; Iqbal, S.; Agrawal, S.; Ramsay, A.G.; Gribben, J.G. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013, 121, 1612–1621. [Google Scholar] [CrossRef] [PubMed]
- McClanahan, F.; Hanna, B.; Miller, S.; Clear, A.J.; Lichter, P.; Gribben, J.G.; Seiffert, M. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood 2015, 126, 203–211. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ding, W.; LaPlant, B.R.; Call, T.G.; Parikh, S.A.; Leis, J.F.; He, R.; Shanafelt, T.D.; Sinha, S.; Le-Rademacher, J.; Feldman, A.L.; et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood 2017, 129, 3419–3427. [Google Scholar] [CrossRef]
- Younes, A.; Brody, J.; Carpio, C.; Lopez-Guillermo, A.; Ben-Yehuda, D.; Ferhanoglu, B.; Nagler, A.; Ozcan, M.; Avivi, I.; Bosch, F.; et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: A phase 1/2a study. Lancet Haematol. 2019, 6, e67–e78. [Google Scholar] [CrossRef]
- Freeman, C.L.; Gribben, J.G. Immunotherapy in Chronic Lymphocytic Leukaemia (CLL). Curr. Hematol. Malig. Rep. 2016, 11, 29–36. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Allard, B.; Allard, D.; Buisseret, L.; Stagg, J. The adenosine pathway in immuno-oncology. Nat. Rev. Clin. Oncol. 2020, 17, 611–629. [Google Scholar] [CrossRef]
- Serra, S.; Horenstein, A.L.; Vaisitti, T.; Brusa, D.; Rossi, D.; Laurenti, L.; D’Arena, G.; Coscia, M.; Tripodo, C.; Inghirami, G.; et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood 2011, 118, 6141–6152. [Google Scholar] [CrossRef]
- Kicova, M.; Michalova, Z.; Coma, M.; Gabzdilova, J.; Dedinska, K.; Guman, T.; Bernatova, S.; Hajikova, M.; Giertlova, M.; Veselinyova, D.; et al. The expression of CD73 on pathological B-cells is associated with shorter overall survival of patients with CLL. Neoplasma 2020, 67, 933–938. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Serra, S.; Vaisitti, T.; Audrito, V.; Bologna, C.; Buonincontri, R.; Chen, S.S.; Arruga, F.; Brusa, D.; Coscia, M.; Jaksic, O.; et al. Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. Blood Adv. 2016, 1, 47–61. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arruga, F.; Serra, S.; Vitale, N.; Guerra, G.; Papait, A.; Baffour Gyau, B.; Tito, F.; Efremov, D.; Vaisitti, T.; Deaglio, S. Targeting of the A2A adenosine receptor counteracts immunosuppression in vivo in a mouse model of chronic lymphocytic leukemia. Haematologica 2021, 106, 1343–1353. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bichi, R.; Shinton, S.A.; Martin, E.S.; Koval, A.; Calin, G.A.; Cesari, R.; Russo, G.; Hardy, R.R.; Croce, C.M. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc. Natl. Acad. Sci. USA 2002, 99, 6955–6960. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cepeda, S.; Cantu, C.; Orozco, S.; Xiao, Y.; Brown, Z.; Semwal, M.K.; Venables, T.; Anderson, M.S.; Griffith, A.V. Age-Associated Decline in Thymic B Cell Expression of Aire and Aire-Dependent Self-Antigens. Cell Rep. 2018, 22, 1276–1287. [Google Scholar] [CrossRef] [Green Version]
- Mkhikian, H.; Hayama, K.L.; Khachikyan, K.; Li, C.; Zhou, R.W.; Pawling, J.; Klaus, S.; Tran, P.Q.N.; Ly, K.M.; Gong, A.D.; et al. Age-associated impairment of T cell immunity is linked to sex-dimorphic elevation of N-glycan branching. Nat. Aging 2022, 2, 231–242. [Google Scholar] [CrossRef]
- Love, M.I.; Huber, W.; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome. Biol. 2014, 15, 550. [Google Scholar] [CrossRef] [Green Version]
- Landau, D.A.; Tausch, E.; Taylor-Weiner, A.N.; Stewart, C.; Reiter, J.G.; Bahlo, J.; Kluth, S.; Bozic, I.; Lawrence, M.; Bottcher, S.; et al. Mutations driving CLL and their evolution in progression and relapse. Nature 2015, 526, 525–530. [Google Scholar] [CrossRef] [Green Version]
- Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6, 11. [Google Scholar] [CrossRef] [Green Version]
- Hofbauer, J.P.; Heyder, C.; Denk, U.; Kocher, T.; Holler, C.; Trapin, D.; Asslaber, D.; Tinhofer, I.; Greil, R.; Egle, A. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia 2011, 25, 1452–1458. [Google Scholar] [CrossRef]
- McClanahan, F.; Riches, J.C.; Miller, S.; Day, W.P.; Kotsiou, E.; Neuberg, D.; Croce, C.M.; Capasso, M.; Gribben, J.G. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Emicro-TCL1 CLL mouse model. Blood 2015, 126, 212–221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Asslaber, D.; Qi, Y.; Maeding, N.; Steiner, M.; Denk, U.; Hopner, J.P.; Hartmann, T.N.; Zaborsky, N.; Greil, R.; Egle, A. B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion. Blood 2019, 134, 1717–1729. [Google Scholar] [CrossRef] [PubMed]
- Hanna, B.S.; Roessner, P.M.; Yazdanparast, H.; Colomer, D.; Campo, E.; Kugler, S.; Yosifov, D.; Stilgenbauer, S.; Schmidt, M.; Gabriel, R.; et al. Control of chronic lymphocytic leukemia development by clonally-expanded CD8(+) T-cells that undergo functional exhaustion in secondary lymphoid tissues. Leukemia 2019, 33, 625–637. [Google Scholar] [CrossRef]
- Sasi, B.; Ethiraj, P.; Myers, J.; Lin, A.P.; Jiang, S.; Qiu, Z.; Holder, K.N.; Aguiar, R.C.T. Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression. Leukemia 2021, 35, 1990–2001. [Google Scholar] [CrossRef] [PubMed]
- Chen, S.; Crabill, G.A.; Pritchard, T.S.; McMiller, T.L.; Wei, P.; Pardoll, D.M.; Pan, F.; Topalian, S.L. Mechanisms regulating PD-L1 expression on tumor and immune cells. J. Immunother. Cancer 2019, 7, 305. [Google Scholar] [CrossRef] [PubMed]
- Sidders, B.; Zhang, P.; Goodwin, K.; O’Connor, G.; Russell, D.L.; Borodovsky, A.; Armenia, J.; McEwen, R.; Linghu, B.; Bendell, J.C.; et al. Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response. Clin. Cancer Res. 2020, 26, 2176–2187. [Google Scholar] [CrossRef] [PubMed]
- Fong, L.; Hotson, A.; Powderly, J.D.; Sznol, M.; Heist, R.S.; Choueiri, T.K.; George, S.; Hughes, B.G.M.; Hellmann, M.D.; Shepard, D.R.; et al. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discov. 2020, 10, 40–53. [Google Scholar] [CrossRef] [Green Version]
- Alcedo, K.P.; Rouse, M.A.; Jung, G.S.; Fu, D.; Minor, M.; Willcockson, H.H.; Greene, K.G.; Snider, N.T. CD73 Maintains Hepatocyte Metabolic Integrity and Mouse Liver Homeostasis in a Sex-Dependent Manner. Cell. Mol. Gastroenterol. Hepatol. 2021, 12, 141–157. [Google Scholar] [CrossRef]
- Figueiro, F.; Muller, L.; Funk, S.; Jackson, E.K.; Battastini, A.M.; Whiteside, T.L. Phenotypic and functional characteristics of CD39(high) human regulatory B cells (Breg). Oncoimmunology 2016, 5, e1082703. [Google Scholar] [CrossRef] [Green Version]
- Alhakeem, S.S.; McKenna, M.K.; Oben, K.Z.; Noothi, S.K.; Rivas, J.R.; Hildebrandt, G.C.; Fleischman, R.A.; Rangnekar, V.M.; Muthusamy, N.; Bondada, S. Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity. J. Immunol. 2018, 200, 4180–4189. [Google Scholar] [CrossRef]
- Rivas, J.R.; Liu, Y.; Alhakeem, S.S.; Eckenrode, J.M.; Marti, F.; Collard, J.P.; Zhang, Y.; Shaaban, K.A.; Muthusamy, N.; Hildebrandt, G.C.; et al. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia. Leukemia 2021, 35, 3188–3200. [Google Scholar] [CrossRef] [PubMed]
- Ray, A.L.; Nofchissey, R.A.; Khan, M.A.; Reidy, M.A.; Lerner, M.R.; Wu, X.; Guo, S.; Hill, S.L.; Weygant, N.; Adams, S.F.; et al. The role of sex in the innate and adaptive immune environment of metastatic colorectal cancer. Br. J. Cancer 2020, 123, 624–632. [Google Scholar] [CrossRef] [PubMed]
- Lee, H.J.; Gallardo, M.; Ma, H.; Zhang, X.; Larsson, C.A.; Mejia, A.; Hornbaker, M.J.; Qi, Y.; Su, X.; Pageon, L.R.; et al. p53-independent ibrutinib responses in an Emu-TCL1 mouse model demonstrates efficacy in high-risk CLL. Blood Cancer J. 2016, 6, e434. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Koch, M.; Reinartz, S.; Saggau, J.; Knittel, G.; Rosen, N.; Fedorchenko, O.; Thelen, L.; Barthel, R.; Reinart, N.; Seeger-Nukpezah, T.; et al. Meta-Analysis Reveals Significant Sex Differences in Chronic Lymphocytic Leukemia Progression in the Emicro-TCL1 Transgenic Mouse Model. Cancers 2020, 12, 1980. [Google Scholar] [CrossRef] [PubMed]
- St Hilaire, C.; Ziegler, S.G.; Markello, T.C.; Brusco, A.; Groden, C.; Gill, F.; Carlson-Donohoe, H.; Lederman, R.J.; Chen, M.Y.; Yang, D.; et al. NT5E mutations and arterial calcifications. N. Engl. J. Med. 2011, 364, 432–442. [Google Scholar] [CrossRef] [PubMed]
- Joolharzadeh, P.; St Hilaire, C. CD73 (Cluster of Differentiation 73) and the Differences Between Mice and Humans. Arter. Thromb. Vasc. Biol. 2019, 39, 339–348. [Google Scholar] [CrossRef] [Green Version]
Experimental Group | Sex | n | Survival (Months) | |
---|---|---|---|---|
Median | Range | |||
Eµ-TCL1tg/wt | F | 25 | 12.0 | 8.3–15.2 |
M | 14 | 12.3 | 8.5–15.6 | |
Eµ-TCL1tg/wt CD73−/− | F | 22 | 12.1 | 8.3–16.3 |
M | 13 | 14.9 | 11.0–16.6 | |
Eµ-TCL1tg/wt CD73−/− + anti-IFN-γ | M | 10 | 12.4 | 10.5–15.6 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Allard, D.; Chrobak, P.; Bareche, Y.; Allard, B.; Tessier, P.; Bergeron, M.A.; Johnson, N.A.; Stagg, J. CD73 Promotes Chronic Lymphocytic Leukemia. Cancers 2022, 14, 3130. https://doi.org/10.3390/cancers14133130
Allard D, Chrobak P, Bareche Y, Allard B, Tessier P, Bergeron MA, Johnson NA, Stagg J. CD73 Promotes Chronic Lymphocytic Leukemia. Cancers. 2022; 14(13):3130. https://doi.org/10.3390/cancers14133130
Chicago/Turabian StyleAllard, David, Pavel Chrobak, Yacine Bareche, Bertrand Allard, Priscilla Tessier, Marjorie A. Bergeron, Nathalie A. Johnson, and John Stagg. 2022. "CD73 Promotes Chronic Lymphocytic Leukemia" Cancers 14, no. 13: 3130. https://doi.org/10.3390/cancers14133130